Scientists Identify Biological Limit to Human Lifespan, Suggesting 190 Years as a Potential Maximum

Scientists from the Skolkovo Institute of Science and Technology have modeled the ultimate limit of the human lifespan, concluding that the accumulation of somatic mutations in DNA may cap human longevity at around 190 years. This finding suggests that while medical advancements can extend life, a natural biological limit exists.

Somatic mutations are minor errors that occur in DNA each time a cell divides. While the body possesses mechanisms to repair these errors, they are not perfect. Most mutations are harmless, but some can lead to cancer or, over time, impair cell function. If all other aging processes were successfully treated, these unrepaired somatic mutations would eventually lead to tissue wear and organ failure, imposing a theoretical maximum lifespan.

The research, led by Dr. Dmitrii Kriukov, aimed to measure the contribution of various aging processes. The study's model, which isolates the effect of somatic mutations, estimates that individuals could live between 146 and 194 years if all other aging mechanisms were eliminated. This is roughly double the current average life expectancy in many developed nations.

While the study acknowledges that some individuals might theoretically live much longer, up to 627 years, the modeling focuses on average lifespans under specific conditions. The findings indicate that somatic mutations, while individually weak drivers of aging, could become critical when combined with other age-related factors.

The researchers noted that different cell types accumulate mutations at varying rates. Cells in the heart and brain, which are largely irreplaceable, tend to accumulate mutations more significantly over time. In contrast, cells in tissues like the skin and liver, which continuously replenish themselves, can sustain their function for longer periods.

This research emerges amidst growing interest in anti-aging technologies and the pursuit of extreme longevity. Figures like tech entrepreneur Bryan Johnson, who reportedly invests millions annually in an anti-aging regimen, exemplify this trend. Similarly, some startups are exploring clinical trials for cellular rejuvenation. However, these findings suggest that the quest for immortality through medical intervention may face fundamental biological constraints imposed by processes like somatic mutation accumulation.